Name Seung-Jung Park
Country Korea (South)
Job Interventional Cardiologist

Other summitMD.com content(s) by This

  1. Percutaneous Intervention of Unprotected Left Main Ostial and Shaft Disease
  2. Left Main Ostial Stenosis after Aortic Valve Replacement
  3. Cypher vs. Taxus ; Taxus vs. Cypher - Is there something different ?
  4. Percutaneous Mitral Valvuloplasty: State of Art
  5. Why Polymer Coated Paclitaxel Stents
  6. Drug-Eluting Stent
  7. Primary Stenting for Unprotected Left Main Coronary Artery Stenosis during AMI
  8. PCI for Chroic Total Occlusion
  9. Coronary Perforation of Proximal LAD after Debulking for LMCA Ostial Stenosis, Treated with PTEE-covered JoStent
  10. Technical Feasibility, Safety, and Clinical Outcome of Stenting of Unprotected Left Main Coronary Artery Bifurcation Narrowing Equipment Overview of DCA Device Percutaneous Intervention of Unprotected Left Main Disease
  11. Percutaneous Intervention of Unprotected left main Disease
  12. Bail-out stenting for Unprotected Left Main Coronary Artery Dissection during Catheter-Based Procedure
  13. Long Cypher?Multicenter Registry Study in Korea
  14. Safety and Effectiveness of Sirolimus Eluting Stent for Left Main Coronary Artery Stenosis
  15. Is bypass surgery needed for elderly patients with left main coronary artery disease? - CON l
  16. Treatment of In-Stent Restenosis : Drug Eluting Stent versus Brachytherapy
  17. Long Cypher Multicenter Registry Study
  18. Long-DES: Study presented in TCT 2004
  19. Aggressive Colesterol Lowering Therapy after PCI(Percutaneous Coronary Intervention)
  20. Drug Eluting Stent: Real World Experience(AMC Registry Study)
  21. LM stenting -Cypher
  22. Safety and Efficacy of Cypher on Complex Lesion
  23. LM Bifurcation Intervention Guideline for COMBAT
  24. How to Treat - Unprotected Left Main Disease
  25. VH Experience in Real World: Asan Medical Center
  26. Nobori Stent, Update
  27. VH-IVUS: Matched and Mismatched
  28. LM Intervention Is Still an Available Option Despite Late Stent Thrombosis?
  29. Left Main Trifurcation Intervention
  30. How Can We Optimize Good Result in the Long Coronary Lesion ?
  31. Long-Term Evaluation of DES vs. BMS; 10-Year Experience from Single Center Registry
  32. Impact of Diabetes on Long-Term Outcomes of Drug-Eluting Stents in Asian Patients
  33. PCI vs CABG in Left Main Disease: Main Registry Update
  34. \"ZEST\" Trial
  35. Tailores Approach with DES for Long Coronary Lesions
  36. Can Carotid Artery Stenting Before CABG Reduce Perioperative Stroke ?
  37. Can SYNTAX Score Be Feasible to Predict Outcomes of LM Revascularization?: Application to MAIN-COMPARE Registry
  38. Prognostic Influence of DM on Long-Term Clinical Outcomes and Stent Thrombosis Following DES Implantation in Asian: AMC Experience
  39. The Impact of Diabetes in the DES Long-Term Outcome
  40. Future Clinical Study for Nobori Stent in Korea
  41. Comparison of Sirolimus- and Paclitaxel-Eluting Stents vs Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial
  42. DECISION CTO_New Horizon in CTO Treatment; Randomized Study Proposal
  43. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
  44. Coronary Intervention
  45. Insight into LM PCI from Main-COMPARE, SYNTAX LM, and Registries
  46. Duration of Dual Antiplatelet Therapy in DES
  47. Xience V in Real Life
  48. PCI in Unprotected Left Main Disease (MAIN-COMPARE, SYNTAX, and Several Registries)
  49. Paradigm Shift to Functional Angioplasty: FFR Guided Decision Making, IVUS Guided Optimization
  50. Case Based Learning
  51. Anatomic vs. Functional Assessment of Coronary Artery Stenosis: Can IVUS-Derived Minimal Lumen Area Predict FFR < 0.8?
  52. Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
  53. Left Main PCI: Where We Are? Where We Are Going?
  54. Is Angiography Enough To Guide LMT PCI? - 'Functional Approach Should Be Considered!'
  55. Pre-COMBAT: LM Disease Revascularization - PCI vs. CABG Randomization Study
  56. Long and Tandem Lesion Intervention: FFR Guided Spot Stenting
  57. It's Not Enough !
  58. Discrepancy between Anatomic vs. Functional Parameters (IVUS vs. FFR)
  59. Invited Case Presentation & Focus Review: FFR Guided Spot Stenting for Tandem Lesion PCI
  60. Why Visual-Functional Mismatches?
  61. Why PCI ? - Rationale for PCI / - Patient & Lesion Selection
  62. Functional Angioplasty - Insight from FFR and IVUS
  63. Is It a Matter of Technique or Concept?: Left Main and Bifurcation PCI
  64. [Debate: Can We Safely Defer PCI Just Based on FFR>0.80?] Yes, Already Proven.
  65. Functional PCI for LM Stenosis: IVUS and FFR Guided
  66. Device Positioning Is Crucial.
  67. FFR Guided and IVUS Supported Functional Angioplasty
  68. Why Visual-functional Mismatches?
  69. New Frontiers in Left Main Intervention; Functional Angioplasty and New Optimizing Criteria
  70. Why Visual-functional Mismatch? New Insight from Computational Simulation and Imaging Data
  71. Clinical Outcomes from RCTs and Registries
  72. When and How We Utilize Imaging and Functional Information in LM Stenting
  73. Now, Do the IVUS-MLA Criteria Need to Be Adjusted ?
  74. Featured Lecture: The Fate of PCI for Multi-Vessel Disease in the Era of COURAGE, SYNTAX, FAME, and FREEDOM
  75. Impact of Functional Angioplasty to Current Practice: Trends in Clinical Outcomes of PCI with Drug Eluting Stents
  76. Impact of Functional Angioplasty in Our Real Practice!
  77. Trend in Outcomes of Percutaneous Coronary Intervention with the Integrated Use of Fractional Flow Reserve and Intravascular Ultrasound
  78. Functional Evaluation Is Necessary !
  79. PCI vs CABG from BARI to SYNTAX: Is the Game over?
  80. TAVI in Korea: How to Avoid Conduction Disturbance..
  81. [Functionally Insignificant, Vulnerable Plaque: Do You Want to Treat?] No, I Don't
  82. Coronary Angiography versus FFR: Why Mismatches
  83. IVUS-MLA and FFR
  84. How Good FFR Guided in Real Practice: Data from Asan PCI and Multivessel Registry
  85. Meta-analysis of LM PCI: PCI Using DES vs. CABG
  86. Do You Want to Treat?: Functionally Insignificant Vulnerable Plaque - No, I Don\'t. We Can\'t Predict Fate of Vulnerable Plaque.
  87. 15-year Temporal Change of LM Revascularization: Lesson from Asan Main Registry
  88. Either FFR or IVUS Is Acceptable, but Choose Your Cutoff Values Wisely!
  89. Temporal Trends and Outcomes of Contemporary LM Treatment: From the Asan Left Main Registry
  90. [FFR Use at CathLab: More & Better] FFR-guided PCI in Routine Practice: Lessons from the AMC Experience
  91. FFR Guided Clinical Practice of Left Main PCI
  92. Asian Multicenter Registry
  93. Can We Prevent DEFER Lesion Event? PREVENT Trial - Design and Rationale
  94. How Good FFR Guided in Real Practice from Asan PCI and Multivessel Registry & IRIS-FFR Registry
  95. IVUS Is Enough!
  96. Impact of FFR
  97. Can We Prevent Future Event?: PREVENT Trial - Design and Rationale
  98. Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
  99. How to Treat? - Functionally Insignificant Vulnerable Plaque: STABLE and PREVENT
  100. Plaque Stabilization and Preemptive BVS: From STABLE to PREVENT
  101. Fate of Deferred Lesion: Insight from Prospective IRIS-FFR Registry
  102. Left Main Disease Is Not Surgical Treatment Any More: Data-Supported 2015
  103. Please Keep It: IVUS-Guidance for LM Stenting
  104. What Happened in Deferred Lesion: Insight from IRIS-FFR Registry
  105. Integrated Approach for LM PCI Using IVUS and FFR
  106. FFR: How to Change Our Practice?
  107. Can We Prevent Events of Vulnerable Plaques?: From STABLE to PREVENT
  108. Relationship Between FFR and Clinical Outcome: Data from IRIS-FFR Registry
  109. Left Main & Bifurcation PCI: Is It a Matter of Technique or Concept?
  110. Case 1: Left Main Disease
  111. Left Main PCI: The Simpler, The Better
  112. FFR and Clinical Outcomes: Evidence Has Never Been Stronger
  113. From STABLE to PREVENT
  114. Physiology-Guidance: Synergetic Hybrid Approach for Complex PCI
  115. Impact of Complete Revascularization for MVD PCI
  116. PREVENT Trial: Update and Insight from Plaque Imaging
  117. Impact of Complete Revascularization for Multivessel PCI
  118. How To Manage Grey Zone FFR?: Data from IRIS FFR Registry
  119. [Debate: Left Main Disease - How to Treat in Contemporary Era?] LM Is No Longer Surgical Disease.
  120. Can BRS Stabilize Vulnerable Plaque?: PREVENT
  121. Future Perspective of Bioresorbable Vascular Scaffolds (ABSORBII, ABSORBIII, AIDA-AMC Registry) : Is It a Crisis or a Chance to Move Forward?
  122. TAVR in Asia, Korea, and AMC
  123. Keynote Lecture on Left Main PCI: Expert\'s Concept and Technique
  124. Top 10 Tips on Left Main PCI
  125. [Debate: Should All CTOs Be Opened?] Con
  126. To Treat or Not to Treat for Gray Zone FFR(0.76-0.80)
  127. All the Data from IRIS-FFR Registry
  128. 10-year Outcomes of MAIN-COMPARE Study: Main and Key Substudies
  129. The Lesson from DECISION-CTO Trial
  130. Integrated Use of FFR and IVUS in LM PCI
  131. PREVENT Trial: Update and Interesting Cases
  132. PCI vs CABG for Left Main and Multivessel Disease
  133. [Featured Lecture] LM-PCI: New Techniques, Concept, and Insights from the LM Pioneer
  134. What Is the Benefit of CTO PCI?: Insights from the DECISION CTO
  135. MAIN COMPARE: 10-Year Follow-up
  136. [Debate: Should All CTOs Be Opened?] Cons
  137. PREVENT: Physiology and Imaging for PREVENTing Future Events
  138. What Is the Practical Approach to LM/MVD Revascularization? - Make It Simple!!
  139. Minimalist TAVR: AMC Experience
  140. Why Mismatching? FFR vs. Angiographic %DS